CD11a Antibody / LFA-1 / ITGAL

CD11a Antibody Overview

CD11a Antibody reagents target CD11a, also known as integrin alpha L (ITGAL), a component of lymphocyte function-associated antigen-1 (LFA-1). This integrin pairs with CD18 to form a heterodimer critical for leukocyte adhesion, trafficking, and immune synapse formation. By binding to intercellular adhesion molecules (ICAMs), LFA-1 regulates T cell activation, cytotoxicity, and migration.

CD11a/LFA-1 is expressed broadly across leukocytes, including T cells, B cells, natural killer (NK) cells, monocytes, and granulocytes. Dysregulation of CD11a is associated with autoimmune disease, chronic inflammation, immunodeficiency, and tumor immune evasion. Because of its central role in immunology and translational research, the CD11a Antibody is indispensable across basic and applied biomedical studies, while the LFA-1 Antibody offers complementary detection of the same complex.

Why Choose CD11a Antibodies from NSJ Bioreagents?

NSJ Bioreagents offers CD11a Antibodies validated for immunohistochemistry, flow cytometry, western blotting, immunofluorescence, and ELISA. Each CD11a Antibody undergoes rigorous testing to ensure specificity, reproducibility, and compatibility with immune-focused workflows.

By choosing CD11a Antibodies from NSJ Bioreagents, researchers gain reagents optimized for clarity and reliability. Our antibodies provide strong detection of CD11a in immune cell subsets, reproducible performance in lysates, and dependable results across both in vitro and in vivo studies. Detailed datasheets, suggested controls, and validated protocols further ensure reproducibility.

Applications of CD11a Antibodies

The CD11a Antibody supports a wide range of immunology and biomedical research applications.

1) Immunology and Immune Cell Profiling

• CD11a Antibodies highlight LFA-1 expression on T cells, B cells, and NK cells.

• The CD11a Antibody supports studies of T cell activation and immune synapse formation.

• LFA-1 Antibody reagents clarify leukocyte adhesion and trafficking.

2) Inflammation and Autoimmunity

• CD11a Antibodies detect altered integrin activity in autoimmune disorders.

• The CD11a Antibody supports research into rheumatoid arthritis, psoriasis, and lupus.

• LFA-1 Antibody reagents validate adhesion pathways in chronic inflammation.

3) Infectious Disease and Host–Pathogen Interactions

• CD11a Antibodies study immune cell trafficking during bacterial and viral infections.

• The CD11a Antibody supports research into immune evasion mechanisms.

• LFA-1 Antibody reagents contribute to host–pathogen studies in immunology.

4) Oncology and Tumor Immunology

• CD11a Antibodies detect LFA-1 expression in tumor-infiltrating lymphocytes.

• The CD11a Antibody supports immuno-oncology research, including checkpoint pathways.

• LFA-1 Antibody reagents help explore tumor immune evasion strategies.

5) Drug Discovery and Therapeutic Development

• CD11a Antibodies evaluate integrin-targeting biologics and small molecules.

• The CD11a Antibody supports pharmacodynamic monitoring of adhesion-blocking therapies.

• LFA-1 Antibody reagents provide translational tools for therapeutic validation.

6) Translational and Clinical Research

• CD11a Antibodies are validated in biomarker-driven clinical trials.

• The CD11a Antibody contributes to immune profiling in precision medicine.

• LFA-1 Antibody reagents ensure reproducibility in translational workflows.

Why Are CD11a Antibodies Important?

CD11a/ITGAL, as part of LFA-1, is a cornerstone of immune adhesion and signaling. The CD11a Antibody equips researchers to study immune cell activation, trafficking, and effector function, while the LFA-1 Antibody expands applications into pathology, drug development, and translational research.

In immunology, CD11a Antibodies clarify how T cells form immune synapses and interact with antigen-presenting cells. In autoimmunity, the CD11a Antibody highlights dysregulated adhesion pathways. In oncology, LFA-1 Antibody reagents reveal how tumor microenvironments manipulate immune infiltration.

Clinically, CD11a is both a biomarker and therapeutic target. Antibodies against CD11a enable reproducible monitoring of immune responses and support the evaluation of therapies designed to modulate integrin pathways.

Conclusion

CD11a (ITGAL) is a vital component of the LFA-1 integrin complex, essential for immune adhesion, signaling, and trafficking. The CD11a Antibody provides researchers and clinicians with validated reagents for studying immune activation, inflammation, and cancer, while the LFA-1 Antibody supports translational applications in diagnostics and therapy development. By ensuring specificity and reproducibility, these antibodies remain indispensable for advancing immunology and improving clinical outcomes.